Core Insights - The competitiveness of the biopharmaceutical industry ultimately reflects the cluster effect [1][11] - The biopharmaceutical industry is a core track of global technological revolution and industrial transformation, serving as a key indicator of regional economic high-quality development [2] Industry Development - The Yangtze River Delta region, centered around Shanghai Zhangjiang and Suzhou BioBAY, has established a first-mover advantage in the biopharmaceutical field due to early policy layouts, dense research resources, and a complete industrial chain [2] - Guangzhou Huangpu District has not lagged despite being a latecomer; it has optimized its policy system, built talent aggregation platforms, and focused on breakthroughs in niche markets, gradually compensating for industrial chain shortcomings [2][12] Key Companies and Innovations - Yunzhou Biotech, founded by Dr. Lan Tian in Huangpu District in 2014, focuses on gene delivery, a critical link between basic research and clinical application [3] - The company developed the world's first intelligent design and ordering platform for gene carriers, integrating over 120 carrier systems and more than 2 million carrier components, significantly lowering the barriers for researchers [4][5] - Yunzhou Biotech has become the world's largest custom gene carrier supplier, serving over 7,000 institutions in more than 130 countries, with a cumulative delivery of over 1 million carriers by September 2024 [5][6] Market Position and Achievements - In 2023, Yunzhou Biotech achieved a valuation of 7 billion, becoming a unicorn and the first biopharmaceutical company in Guangzhou to reach this status [6] - The company has established a full-service capability in the gene drug development chain, including CRO and CDMO services, with its products approved for clinical trials in the U.S. [6][7] Competitive Landscape - Innovation in drug development is a core competitive advantage in the biopharmaceutical industry, with companies like Kangfang Biopharma emerging as leaders in the field [8] - Kangfang Biopharma has developed over 50 innovative drug candidates, with 24 products undergoing clinical trials, and has successfully commercialized 7 first-class new drugs [10] Ecosystem and Collaboration - Huangpu District's "bending overtaking" is not merely the success of a single enterprise but a result of creating a quality industrial ecosystem that fosters collaboration between leading external companies and local enterprises [12] - The presence of major companies like Hengrui Medicine and Nuocheng Jianhua in Huangpu has attracted a network of supporting enterprises, enhancing the regional industrial chain [13][14]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月2日，恒瑞医药发布公告称，公司近日收到国家药品监 督管理局核准签发关于HRS—7172片的《药物临床试验批准通知书》，同意该品单药在携带RAS突变或 扩增的晚期实体瘤患者中开展临床试验。 ...

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, an antibody-drug conjugate targeting HER3, aimed at treating advanced solid tumors [1] Group 1 - The clinical trial will focus on the safety, tolerability, and efficacy of SHR-A2009 in combination with anti-tumor therapy in patients with advanced solid tumors [1] - SHR-A2009 specifically binds to HER3 on the surface of tumor cells, leading to internalization and subsequent release of cytotoxic agents within lysosomes to kill cancer cells [1]

恒瑞医药(600276.SH)公告，公司收到国家药品监督管理局核准签发关于HRS-7172片的《药物临床试验 批准通知书》，同意本品单药在携带RAS突变或扩增的晚期实体瘤患者中开展临床试验。HRS-7172片 是公司自主研发的新型抗肿瘤小分子抑制剂。 ...

恒瑞医药（600276）(600276.SH)公告，公司收到国家药品监督管理局核准签发关于HRS-7172片的《药 物临床试验批准通知书》，同意本品单药在携带RAS突变或扩增的晚期实体瘤患者中开展临床试验。 HRS-7172片是公司自主研发的新型抗肿瘤小分子抑制剂。 ...

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, an antibody-drug conjugate targeting HER3, aimed at treating advanced solid tumors [1] Group 1 - The clinical trial will focus on the safety, tolerability, and efficacy of SHR-A2009 in combination with anti-tumor therapy in patients with advanced solid tumors [1] - SHR-A2009 specifically binds to HER3 on the surface of tumor cells, facilitating its internalization and subsequent release of cytotoxic agents within lysosomes to kill cancer cells [1]

恒瑞医药公告，截至2025年8月31日，公司尚未开始实施股份回购。公司回购股份方案已于2025年8月20 日通过董事会决议，同意使用自有资金以集中竞价交易方式回购股份，用于实施A股员工持股计划。回 购价格不超过90.85元/股，资金总额不低于10亿元且不超过20亿元。回购期限为自董事会审议通过回购 股份方案之日起12个月以内。 ...

Group 1 - The core point of the article is that Heng Rui Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of HRS-7172 tablets, a new type of small molecule inhibitor for cancer treatment developed by the company [1] Group 2 - HRS-7172 tablets are positioned as a novel anti-tumor drug, indicating the company's focus on innovative oncology therapies [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-A2009, an antibody-drug conjugate targeting HER3 [1] Group 1 - SHR-A2009 specifically binds to HER3 on the surface of tumor cells, leading to internalization and transport to lysosomes, where it releases free toxins to kill tumor cells [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-137 江苏恒瑞医药股份有限公司 关于回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/8/21 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 8 月 20 8 | 日~2026 | 年 | 月 | 19 | 日 | | 预计回购金额 | 100,000万元~200,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 0万股 | | | | | | | 累计已回购股数占总股本比例 | 0% | | | | | | | 累计已回购金额 | 0万元 | | | | | | | 实际回购价格区间 | /元 ...